Inventory Huddle #5
May 6, 2020

Both audio and visuals are available through the Skype Meeting Broadcast link and are accessible via any browser.

During the call, please submit questions via the Skype window.
Today’s Speakers

Blake Jarrell
Vice President, National Accounts

Heather Zenk, RPh, PharmD
Senior Vice President, Replenishment & Manufacturer Operations

Both audio and visuals are available through the Skype Meeting Broadcast link and are accessible via any browser.
We want to hear how AmerisourceBergen is doing to support you during the COVID-19 crisis. Share your feedback via a 2-minute survey.

Remdesivir: AmerisourceBergen distributing based on direction from FEMA/HHS

- May 1: Food and Drug Administration granted remdesivir an Emergency Use Authorization (EUA) for patients with severe COVID-19 in the hospital setting
- U.S. Federal Government is directing the distribution to eligible hospitals – retail and specialty pharmacies are not eligible
  - Gilead and AmerisourceBergen are not deciding which hospitals will receive remdesivir
- AmerisourceBergen is the sole distributor for the donated remdesivir
- As hospitals are identified by the U.S. Government as a recipient, they will be proactively contacted by an AmerisourceBergen representative
Remdesivir - Resources


- National Remdesivir Donation Inquiry Line: 1-877-987-4987
  - Do not contact Customer CARE with remdesivir questions (use dedicated resources)

- Dedicated e-mail box for inquiries on eligibility & designation for donation: remdesivir@amerisourcebergen.com

- For information on clinical trials that are testing the use of remdesivir in COVID-19, visit www.clinicaltrials.gov

- For additional medical information about remdesivir, please visit www.askgileadmedical.com/remdesivir or call 1-866-MEDI-GSI (1-866-633-4474) Monday – Friday, 6am – 4pm PT
State Re-openings: Planning for Elective Procedures & Possible Subsequent Regional COVID-19 Surges

- **Preparing to meet increased demand as elective procedures resume**
  - If you expect a significant increase in product demand for specific items, send estimated usage to Customer CARE (or Account Services if applicable), who will work with Replenishment Operations
  - AmerisourceBergen will work with manufacturers to anticipate demand changes not reflected by recent purchase history
  - Anticipate constraints as elective procedures & COVID-19 treatment (e.g., injectable narcotics) overlap

- **Preparing for possible subsequent surges of COVID-19** cases as States and regions ease stay-at-home orders
  - Order the products you need for true current patient demand – try not to stock in advance to ease strain on supply chain
  - Upcoming flu season will compound risk for increased hospital admissions; continue to encourage flu vaccines for all staff and patients
Inventory Insights

Top 15 Omit Items Account for 46% of Omits

- Albuterol & MDIs
- Acid reducers (famotidine)
  - Driven by Zantac recall & demand for injectable famotidine
- Sedation groups
  - Paralytics
  - Injectable narcotics
  - Some relief in propofol availability from Pfizer

Inventory Demand Continues to Normalize

- Continue tracking 90-day refill cycle after COVID initial surge (early June)
- Continued focus on preparation for elective procedures
- Physician and oncology demand starting to return to pre-COVID levels
COVID-19 Test Kits

- AmerisourceBergen has been working to source antibody (serology) COVID-19 test kits for our customers. The FDA has issued Emergency Use Authorization (EUA) for some serology tests, however, others are being marketed without EUA or other FDA approval.
  - New FDA requirements for manufacturers to submit data.

- The quality, efficacy and accuracy of currently marketed test kits varies greatly, and the sourcing has been challenging. AmerisourceBergen does not have confidence in the quality of serology test kits that have been offered to us.

- As a result, we’ve made the decision not to distribute COVID-19 serology tests at this time.

- Near-term efforts will focus on continuously monitoring the market for reliable test offerings, helping prepare and educate our customers and staying up-to-date on our customers’ needs.
Global Supply Chain

- India’s stay-at-home guidance could be extended through mid-to late-May, but restrictions have started to ease in regions with few or zero cases
- Manufacturer challenges with staffing, mobility, air cargo, and absenteeism; continue to mitigate risk
- Logistical challenges: production management, air freight, and customs clearance
- Many US-manufacturers with India facilities still have inventory in the supply chain – no immediate disruptions are foreseen
- AmerisourceBergen is still being held to historical purchasing amounts (January/February demand vs. current) in many cases

Updates from the DEA

- AmerisourceBergen continues to work with HDA to communicate changing demand due to COVID-19 (with an eye on controlled substance availability)
- Distributors remain responsible for maintaining controls against diversion
- Distributors obtain and review customer utilization reports as part of due diligence process
- DEA is aware that registrants may have changed their ordering patterns in order to fulfill their patients' needs
- Distributors still required to obtain an explanation for the deviation from their normal ordering patterns and document the changes in ordering behavior and the possible reasons for it in its due diligence file for each customer
Additional Health Screening Measures for AmerisourceBergen Associates & Vendors

- Implemented health screening questionnaire and temperature testing at all sites across the U.S.
We are united in our responsibility to create healthier futures.
Please submit questions directly in the Skype window